The mission of the MMRF is to urgently and aggressively fund research that will lead to the development of new treatments for multiple myeloma, an incurable blood cancer. As the world's number-one private funder of multiple myeloma research, the MMRF has raised more than $225 million to fund over 130 laboratories worldwide. The payback on our investment has been significant. Six new breakthrough treatments — Thalomid, Velcade, Revlimid, Doxil, Kyprolis and Pomalyst — are extending the lives of myeloma patients worldwide and are now being explored in a range of over 30 other cancers, including ovarian cancer, breast cancer, prostate cancer, leukemia, and Non-Hodgkin's lymphoma.

Established: 1998




Please wait... Please wait...